Skip to main content
. 2023 May 18;257:115503. doi: 10.1016/j.ejmech.2023.115503

Fig. 1.

Fig. 1

Chemical structures of representative SARS-CoV-2 inhibitors. Azvudine, a self-developed oral SARS-CoV-2 RdRp inhibitor, approved by the NMPA of China; VV116, the first deuterated oral RdRp candidate, approved by the NMPA of China; FB2001, China's first inhaled Mpro clinical candidate; WPV01, non-covalent Mpro inhibitor; Proxalutamide, ACE2 inhibitor, approved for emergency use in Uruguay; Cepharanthine, natural product-derived ACE2 inhibitor.